- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Ha Kung Wong Discusses Public Interest and Drug Competition
Public interest and what is in the best public interest can vary from court to court, and in the case of Amgen v Sanofi, it has yet to be determined if public interest will be considered, explained Ha Kung Wong, JD, partner at Fitzpatrick, Cella, Harper and Scinto.
Amgen v Sanof
Public interest and what is in the best public interest can vary from court to court, and in the case of i, it has yet to be determined if public interest will be considered, explained Ha Kung Wong, JD, partner at Fitzpatrick, Cella, Harper and Scinto.
Transcript
Will the public interest in having competition within drug classes, such as in the ongoing litigation concerning PCSK9 patents, have an impact on the courts’ rulings?
Well, public interest is an interesting question because of lot of that can be subjective from court to court. But historically, competition per se hasn’t had much of an impact on courts’ rulings relating to small molecule drugs and medical devices. So in those situations, where the courts haven’t seen much evidence of physician preference for or greater efficacy of an infringing product, they will generally determine that the public interest actually lies in having a strong patent system and not in having just competing products in a market for the sake of competition.
But, where the courts have seen evidence of physician preference or product superiority they do tend to find that the public interest lies in keeping a superior product on the market. In Amgen v Sanofi, for example, Sanofi is now trying to demonstrate that the clinical trials suggest that its PCSK9 inhibitor is superior. Regardless, it’s yet to be seen if the public interest factor would be dispositive in this situation, and if not, to what extent it will be considered.
In this interview with The American Journal of Managed Care®, Katie Queen, MD, addresses the complexity of obesity as a medical condition, pivoting to virtual care while ensuring that patients who lived in a rural location continued to receive adequate care, and the importance of integrating awareness of obesity and chronic disease prevention into local food culture.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Recent T1D Research Contradicts Common Assumptions About Patients
November 15th 2023Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.
Read More
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
